Ever-advancing chronic myeloid leukemia treatment

International Journal of Clinical Oncology

Volumn 19, Issue 1, 2014, Pages 3-9

  Kimura, Shinya ^a   Ando, Toshihiko ^a   Kojima, Kensuke ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib; Tyrosine kinase

Indexed keywords

BENZAMIDES; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; THIAZOLES;

EID: 84894592208     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0641-7     Document Type: Review

References (31)

1. Druker BJ, Talpaz M, Resta DJ, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037
2. O'Brien SG, Guilhot F, Larson RA, et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1104
3. Baccarani M, Deininger MW, Rosti G, et al. (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872-884
4. O'Brien S, Abboud CN, Akhtari M, et al. (2012) NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 2, 2013. Available at: NCCN.org. Accessed Sep 17, 2012
5. Deininger M, O'Brien SG, Guilhot F, et al. (2009) International randomized study of Interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114:462 (Abstract 1126)
6. Gorre ME, Mohammed M, Ellwood K, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880
7. Hegedus T, Orfi L, Seprodi A, et al. (2002) Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587:318-325
8. Wu J, Meng F, Lu H, et al. (2008) Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib resistant chronic myelogenous leukemia cells. Blood 111:3821-3829
9. White DL, Dang P, Engler J, et al. (2010) Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 28:2761-2767
10. + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103:14907-14912
11. Ng KP, Hillmer AM, Chuah CT, et al. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18:521-528
12. Tanaka R, Kimura S, Ashihara E, et al. (2011) Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Lett 312:228-234
13. Khorashad JS, Kelley TW, Szankasi P, et al. (2013) BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 121:489-498
14. Sherbenou DW, Hantschel O, Kaupe I, et al. (2010) BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 116:3278-3285
15. Shah NP, Tran C, Lee FY, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401
16. Deguchi Y, Kimura S, Ashihara E, et al. (2008) Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32:980-983
17. Hochhaus A, Baccarani M, Deininger M, et al. (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200-1206
18. Shah NP, Kantarjian HM, Kim DW, et al. (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204-3212
19. Kantarjian H, Shah NP, Hochhaus A, et al. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270
20. Kim DH, Kamel-Reid S, Chang H, et al. (2009) Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 94:135-139
21. Weisberg E, Manley PW, Breitenstein W, et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129-141
22. Kantarjian HM, Giles F, Gattermann N, et al. (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540-3546
23. Saglio G, Kim DW, Issaragrisil S, et al. (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259
24. Golas JM, Arndt K, Etienne D, et al. (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 3:375-381
25. Kimura S, Naito H, Segawa H, et al. (2005) NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106:3948-3954
26. Kantarjian H, le Coutre P, Cortes J, et al. (2010) Phase I study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias post-imatinib resistance or intolerance. Cancer 16:2665-2672
27. Imam SZ, Trickler W, Kimura S, et al. (2013) Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model. PLoS One 8:e65129
28. O'Hare T, Shakespeare WC, Zhu X, et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401-412
29. Kimura S (2010) Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone (Second Edition). Recent Pat Anticancer Drug Discov 2010:116-131
30. Saussele S, Lauseker M, Gratwohl A, et al. (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115:1880-1885
31. Mahon FX, Réa D, Guilhot J, et al. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035